| Completed | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced S NCT02775292 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Pocket Phantom Tool in Improving Accuracy of Quantitative PET/CT Imaging of Patients With Solid Tumors NCT02822365 | University of Washington | — |
| Active Not Recruiting | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy NCT02432963 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent NCT02627430 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors NCT01971489 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Improving Communication in Older Cancer Patients and Their Caregivers NCT02107443 | Supriya Mohile | N/A |
| Completed | Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer NCT02054741 | Supriya Mohile | N/A |
| Completed | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies NCT02116777 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors NCT01654965 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by NCT01625156 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by NCT01548482 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cann NCT01093092 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed b NCT01375829 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advan NCT01281176 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Brea NCT01263145 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metasta NCT01281150 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinom NCT01264432 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Remo NCT01276496 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors NCT01218620 | National Cancer Institute (NCI) | Phase 1 |
| Completed | ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors NCT01154426 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responde NCT00813423 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum NCT01039155 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme NCT01122888 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies NCT01061749 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Selumetinib in Cancers With BRAF Mutations NCT00888134 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metas NCT00878163 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer NCT00535119 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tu NCT00499135 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tum NCT00410553 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Remov NCT00334789 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cance NCT00217373 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic S NCT00070252 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors NCT00045201 | National Cancer Institute (NCI) | Phase 1 |